India, Nov. 18 -- Immuneering Corporation (IMRX), a late-stage oncology company, on Wednesday released data supporting lead drug candidate Atebimetinib as a potential therapeutic for pancreatic and thyroid cancer.
Atebimetinib is a Deep Cyclic inhibitor of MEK, a pathway that controls cellular proliferation and mutations in tumor cells. Currently available inhibitors of such pathways offer only temporary benefits, as tumors acquire new mutations in the MAPK pathway. The drug acts by mitigating selective pressure that drives these resistance mechanisms, thus providing more durable anti-tumor activity.
Data From Pancreatic Cancer Models:
The drug is currently under evaluation in the Phase 3 MAPKeeper 301 trial in combination with mGnP for ...